HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, D. Articles by Kenyon, N. S. Search for Related Content PubMed PubMed Citation Articles by Han, D. Articles by Kenyon, N. S. Social Bookmarking                What's this?

Assessment of Cytotoxic Lymphocyte Gene Expression in the Peripheral Blood of Human Islet Allograft Recipients

Elevation Precedes Clinical Evidence of Rejection

¹ Diabetes Research Institute, University of Miami School of Medicine, Miami, Florida
² Department of Medicine, University of Miami School of Medicine, Miami, Florida
³ Department of Surgery, University of Miami School of Medicine, Miami, Florida

Studies in nonhuman primates have demonstrated that elevation of the cytotoxic lymphocyte (CL) genes granzyme B, perforin, and Fas ligand in peripheral blood precedes islet allograft rejection. The purpose of this study was to determine whether this approach has utility for prediction of human islet allograft loss. We studied 13 patients who had long-term type 1 diabetes and were treated with steroid-free immunosuppression and given sequential islet cell infusions. All recipients became insulin independent, and eight of them experienced deterioration in glycemic control, followed by reinitiation of insulin therapy. Frequent peripheral blood samples were collected to monitor CL gene mRNA levels with real-time PCR. For the eight back-to-insulin patients, there was a clear elevation of CL gene mRNA levels 25–203 days before the onset of frequent hyperglycemia. Granzyme B was the most reliable indicator of ongoing graft loss. Additional correlations with infection were noted; however, evidence of sensitization in antidonor mixed lymphocyte reaction was observed in seven of eight patients who experienced partial graft loss, whereas this was not seen when upregulated CL gene expression was associated with infection. The results suggest that, when taken into consideration with other clinical parameters, elevated CL gene levels may enable prediction of islet allograft loss.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. PILEGGI, L. COBIANCHI, L. INVERARDI, and C. RICORDI Overcoming the Challenges Now Limiting Islet Transplantation: A Sequential, Integrated Approach Ann. N.Y. Acad. Sci., October 1, 2006; 1079(1): 383 - 398. [Abstract] [Full Text] [PDF]

				E. Estella, M. D. McKenzie, T. Catterall, V. R. Sutton, P. I. Bird, J. A. Trapani, T. W. Kay, and H. E. Thomas Granzyme B-Mediated Death of Pancreatic {beta}-Cells Requires the Proapoptotic BH3-Only Molecule Bid. Diabetes, August 1, 2006; 55(8): 2212 - 2219. [Abstract] [Full Text] [PDF]

				E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R.T. Lakey, and A.M. J. Shapiro Five-Year Follow-Up After Clinical Islet Transplantation Diabetes, July 1, 2005; 54(7): 2060 - 2069. [Abstract] [Full Text] [PDF]